Examination of the Mechanism(s) Involved in Doxorubicin-Mediated Iron Accumulation in Ferritin: Studies Using Metabolic Inhibitors, Protein Synthesis Inhibitors, and Lysosomotropic Agents

Molecular Pharmacology

Volumn 65, Issue 1, 2004, Pages 181-195

  Kwok, J C ^a   Richardson, D R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALOXISTATIN; AMMONIUM CHLORIDE; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHLOROQUINE; DOXORUBICIN; ENZYME INHIBITOR; FERRITIN; IRON; IRON 59; LACTACYSTIN; LEUPEPTIN; LYSOSOMOTROPIC AGENT; METABOLIC INHIBITOR; METHYLAMINE; PROTEASOME; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; CARDIOTOXICITY; CATABOLISM; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ENERGY METABOLISM; HUMAN; HUMAN CELL; IRON KINETICS; IRON METABOLISM; LYSOSOME; METABOLIC INHIBITION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION;

ANTHRACYCLINES; BIOLOGICAL TRANSPORT; CYCLOHEXIMIDE; CYSTEINE ENDOPEPTIDASES; CYTOSOL; DOXORUBICIN; FERRITINS; HUMANS; IRON; IRON RADIOISOTOPES; LYSOSOMES; MITOCHONDRIA; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SYNTHESIS INHIBITORS; TUMOR CELLS, CULTURED;

EID: 1642576976     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.1.181     Document Type: Article

References (40)

1. Bienfait HF and Van der Briel ML (1980) Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen. Biochim Biophys Acta 631:507-510.
2. Bolann BJ and Ulvik RJ (1987) Release of iron from ferritin by xanthine oxidase. Role of the superoxide radical. Biochem J 243:55-59.
3. Corsi B, Cozzi A, Arosio P, Drysdale J, Samtambrogio P, Campanella A, Biasiotto G, Albertini A, and Levi S (2002) Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem 277:22430-22437.
4. Darnell G and Richardson DR (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94:781-792.
5. Dick LR, Cruikshank AA, Greiner L, Melandri FD, Nunes SL, and Stein RL (1996) Mechanistic studies on the activation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J Biol Chem 271:7273-7276.
6. Funk F, Lenders JP, Crichton RR, and Schneider W (1985) Reductive mobilisation of ferritin iron. Eur J Biochem 152:167-172.
7. Gianni L and Myers C (1992) The role of free radical formation in the cardiotoxicity of anthracycline, in Cancer Treatment and the Heart (Muggia FM, Green MD, and Speyer JL eds) pp 9-46, Johns Hopkins University Press, Baltimore.
8. Giljaard H (1980) Genetic Metabolic Diseases: Early Diagnosis and Prenatal Analysis, Elsevier/North Holland Biomedical Press, Amsterdam.
9. Harrison PM and Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161-203.
10. Hernandez-Yago J, Knecht E, Martinez-Ramon A, and Grisola S (1980) Autophagy of ferritin incorporated into the cytosol of Hela cells by liposomes. Cell Tissue Res 205:303-309.
11. Hurwitz SJ, Terashima M, Mizunuma N, and Slapak CA (1997) Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood 89:3745-3754.
12. Jin W, Takagi H, Pancorbo B, and Theil EC (2001) "Opening" the ferritin pore for iron release by mutation of conserved amino acids at interhelix and loop sites. Biochemistry 40:7525-7532.
13. Kiyomiya K, Matsuo S, and Kurebe M (2001) Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 61:2467-2471.
14. Klohs WD and Steinkampf RW (1988) The effect of lysosomotrophic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol 34:180-185.
15. Knight CG and Barrett AJ (1976) Interaction of human cathepsin D with the inhibitor pepstatin. Biochem J 155:117-125.
16. Kotamraju S, Chitambar CR, Kalivendi S, Joseph J, and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179-17187.
17. Kwok JC and Richardson DR (2002a) Anthracycline-mediated alterations in iron regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888-900.
18. Kwok JC and Richardson DR (2002b) The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Haematol Oncol 42:65-78.
19. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
20. Lee DH and Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8:397-403.
21. Link G, Tirosh R, Pinson A, and Hershko C (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127:272-278.
22. Matteoni R and Kreis TE (1987) Translocation and clustering of endosomes and lysosomes depends on microtubules. J Cell Biol 105:1253-1265.
23. McGowan EB, Becker E, and Detwiler TC (1989) Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem Biophys Res Commun 158:432-435.
24. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 cytosolic fractions from human myocardium. FASEB J 12:541-552.
25. Ohkuma S and Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327-3331.
26. Ohshita T, Nikawa T, Towatari T, and Katunuma N (1992) Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro. Eur J Biochem 209:223-231.
27. Persson HL, Nilsson KJ, and Brunk UT (2001) Novel cellular defenses against iron and oxidation: ferritin and autophagocytosis preserve lysosomal stability in airway epithelium. Redox Rep 6:57-63.
28. Pillay CS, Elliott E, and Dennison C (2002) Endolysosomal proteolysis and its regulation. Biochem J 363:417-429.
29. Radisky DC and Kaplan J (1998) Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem J 336:201-205.
30. Richardson DR (1999) Role of ceruloplasmin and ascorbate in cellular iron release. J Lab Clin Med 134:454-465.
31. Richardson DR and Baker E (1990) The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta 1053:1-12.
32. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxyl-1-napthylaldehyde benzoyl hydrazone. Blood 89:3025-3038.
33. Rickwood D and Patel D (1995) Fractionation and analytical methods, in Cell and Molecular Biology: Essential Data, Wiley and Sons, Chichester, New York.
34. Roberts S and Bomford A (1988) Ferritin iron kinetics and protein turnover in K562 cells. J Biol Chem 263:19181-19187.
35. Rudeck M, Volk T, Sitte N, and Grune T (2000) Ferritin oxidation in vitro: implication of iron release and degradation by the 20S proteasome. IUBMB Life 49:451-456.
36. Singal PK, Segstro RJ, Singh RP, and Kutryk MJ (1985) Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1:139-147.
37. Speyer BE and Fielding J (1979) Ferritin as a cytosol iron transport intermediate in human reticulocytes. J Br Haematol 42:255-267.
38. Vinogradova MV, Michaud L, Mezentsev AV, Lukong KE, El-Alfy M, Morales CR, Potier M, and Pshezhetsky AV (1998) Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation. Biochem J 330:641-650.
39. Watts RN and Richardson DR (2001) Nitrogen monoxide (NO) and glucose. Unexpected links between energy metabolism and NO-mediated iron mobilization from cells. J Biol Chem 276:4724-4732.
40. Zunino F, Pratesi G, and Perego P (2001) Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 61:933-938.